Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Continuous Rotigotine Delivery in PD and RLS: Clinical Insig
2026-05-03
This review details the development of the rotigotine transdermal system, a continuous dopamine D2/D3 receptor agonist therapy, for Parkinson’s disease and restless legs syndrome. Its pharmacokinetic profile, clinical efficacy, and impact on both motor and non-motor symptoms are examined, highlighting translational implications for researchers using dopaminergic pathway modulators.
-
MALAT1-miR-125b-STAT3 Axis Regulates PCT in Sepsis: Mechanis
2026-05-02
This study elucidates how the long non-coding RNA MALAT1 regulates procalcitonin (PCT) expression in sepsis through its interaction with miR-125b and STAT3. Using patient samples and mechanistic in vitro assays, the findings reveal a potential molecular target for improving sepsis diagnosis and therapy.
-
S Tag Peptide: Practical Guide for Fusion Tag Applications
2026-05-01
The S Tag Peptide enables efficient recombinant protein detection and purification workflows by improving solubility and providing a robust target for anti-S-Tag antibody detection. It is not suitable for applications requiring direct enzymatic activity or use in ethanol-based buffers. Researchers should use this reagent within its solubility and stability constraints to avoid workflow interruptions.
-
Anlotinib Hydrochloride as a Selective VEGFR2 Inhibitor in C
2026-05-01
This study delineates the preclinical characterization of anlotinib hydrochloride, highlighting its potency and selectivity as a multi-target tyrosine kinase inhibitor, particularly against VEGFR2. The paper underscores its robust anti-angiogenic activity and superior in vivo efficacy compared to established TKIs, offering valuable insights for translational cancer research.
-
ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR
2026-04-30
This study introduces a combinatorial library of ROS-responsive, biodegradable lipid nanoparticles that selectively deliver mRNA to tumor cells by exploiting their elevated ROS microenvironment. The approach demonstrates enhanced antitumor efficacy by enabling targeted mRNA release and functional gene expression, opening new avenues for precision mRNA therapeutics.
-
PINK1 Deficiency Drives Mitochondrial Iron Accumulation in C
2026-04-30
This study uncovers how loss of PINK1, a mitophagy regulator, leads to mitochondrial iron overload and promotes colon tumorigenesis. Targeting mitochondrial iron transport emerges as a promising therapeutic avenue, particularly in colorectal cancers with low PINK1 expression.
-
MALAT1/miR-125b/STAT3 Axis Controls PCT Expression in Sepsis
2026-04-29
This study uncovers a mechanistic axis in which the long non-coding RNA MALAT1 regulates procalcitonin (PCT) expression in sepsis via targeted modulation of the miR-125b/STAT3 pathway. These insights advance molecular understanding of sepsis biomarkers and open new avenues for diagnostic and therapeutic strategies.
-
Sumatriptan’s Emerging Anti-Inflammatory Role: Systematic Re
2026-04-29
Ala et al. systematically reviewed evidence supporting sumatriptan’s anti-inflammatory properties beyond its established use in migraine. Their analysis reveals that sumatriptan modulates key inflammatory pathways, suggesting potential for repositioning in diverse inflammatory conditions.
-
Oteseconazole (VT-1161) for Precision Antifungal Assays
2026-04-28
Oteseconazole (VT-1161) delivers high selectivity and potency for targeting Candida, including fluconazole-resistant strains, with minimal drug interaction risk. This guide details robust experimental workflows, protocol optimizations, and troubleshooting anchored in the latest pharmacokinetic and mechanistic insights.
-
Dextran Sulfate Sodium Salt (MW 35000-45000): Innovations in
2026-04-28
Explore the unique capabilities of Dextran sulfate sodium salt (MW 35000-45000) in advanced intestinal inflammation models, with new insights into epithelial repair mechanisms. This in-depth analysis highlights its role in ulcerative colitis research and practical assay optimization.
-
Anlotinib for Intra-Abdominal Desmoplastic Small Round Cell
2026-04-27
This case report documents the first use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT). The findings suggest that anlotinib may offer a promising therapeutic option for this rare and aggressive malignancy, with manageable toxicity and measurable tumor response.
-
Tigecycline: Glycylcycline Antibiotic for MDR Bacteria Resea
2026-04-27
Tigecycline, a pioneering glycylcycline antibiotic, enables robust workflows for studying multidrug-resistant bacteria in both in vitro and in vivo models. Explore optimized assay designs, troubleshooting strategies, and protocol parameters rooted in recent transmission studies and APExBIO’s validated supply chain.
-
mRNA-LNP Tailored CAR Macrophages Enhance Cancer Immunothera
2026-04-26
This study introduces a macrophage-targeted mRNA lipid nanoparticle system for in situ programming of chimeric antigen receptor macrophages (CAR-Ms) to combat peritoneal metastasis. The approach enables the rapid testing of CAR intracellular domains, revealing formats that synergize with checkpoint blockade and reshape the tumor microenvironment, with implications for translational oncology research.
-
BicD and MAP7 Synergistically Activate Drosophila Kinesin-1
2026-04-25
This study elucidates how Drosophila BicD and MAP7 coordinately relieve auto-inhibition and enhance processivity of homodimeric kinesin-1 motors. These findings provide mechanistic insight into adaptor-motor regulation, advancing our understanding of intracellular transport and offering a foundation for experimental designs that interrogate motor activity modulation.
-
Vorinostat (SAHA): Precision HDAC Inhibition for Epigenetic
2026-04-24
Explore how Vorinostat (suberoylanilide hydroxamic acid) uniquely empowers epigenetic modulation in oncology. This article provides a deep dive into its mechanism, advanced workflows, and practical assay insights beyond standard protocols.